Developmental trajectories of attention-deficit/hyperactivity disorder into adulthood and aging : multimorbidity and polypharmacy
Author: Zhang, Le
Date: 2023-02-10
Location: Lecture Hall Petrén, Nobels väg 12B, Karolinska Institutet, Solna
Time: 09.00
Department: Inst för medicinsk epidemiologi och biostatistik / Dept of Medical Epidemiology and Biostatistics
View/ Open:
Thesis (1.257Mb)
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by developmentally inappropriate levels of inattentiveness, hyperactivity, and impulsivity. Previous studies have shown that symptoms of ADHD often persist into adulthood. In addition, substantial psychiatric comorbidities as well as adverse somatic outcomes could emerge across the lifespan. However, health outcomes of ADHD in adulthood and old age, and the long-term consequences of ADHD medications remain understudied.
In study I, we described the patterns of co-medication and polypharmacy with ADHD medications among adults. Among all major classes of somatic medications, respiratory system medications, alimentary tract and metabolism system medications, and cardiovascular system medications have the highest odds of being dispensed when comparing individuals using ADHD medication to controls.
In study II, we examined whether ADHD is linked with Alzheimer’s disease (AD) and other dementias within families. We found ADHD was associated with AD and any dementia across generations, for example, parents of individuals with ADHD were associated with a 55% increased risk of AD compared to parents of individuals without ADHD. The associations attenuated with decreasing genetic relatedness. The increased risk associated with ADHD was higher for early-onset AD than that for late-onset AD.
In study III, we performed a systematic review and meta-analysis to examine the association between ADHD medications and a broad range of cardiovascular diseases (CVDs). Nineteen studies with 4 million participants were included. The results show there was no statistically significant association between ADHD medication use and CVDs in general, but the pooled risk ratio does not exclude a modest risk increase, especially for the risk of cardiac arrest and tachyarrhythmias. The risk of CVDs among females and those with pre-existing CVDs, and the long-term risk associated with ADHD medication use require further evaluation.
In study IV, we assessed the association between the long-term use of ADHD medication and the risk of CVDs using a nested case-control design. We found longer duration of ADHD medication use was associated with an increased risk of CVDs compared with non-use. A one-year increase use of ADHD medication was associated with a 7% of increased risk of CVDs. A higher cumulative dose of ADHD medications was also associated with an increased risk of CVDs.
In study I, we described the patterns of co-medication and polypharmacy with ADHD medications among adults. Among all major classes of somatic medications, respiratory system medications, alimentary tract and metabolism system medications, and cardiovascular system medications have the highest odds of being dispensed when comparing individuals using ADHD medication to controls.
In study II, we examined whether ADHD is linked with Alzheimer’s disease (AD) and other dementias within families. We found ADHD was associated with AD and any dementia across generations, for example, parents of individuals with ADHD were associated with a 55% increased risk of AD compared to parents of individuals without ADHD. The associations attenuated with decreasing genetic relatedness. The increased risk associated with ADHD was higher for early-onset AD than that for late-onset AD.
In study III, we performed a systematic review and meta-analysis to examine the association between ADHD medications and a broad range of cardiovascular diseases (CVDs). Nineteen studies with 4 million participants were included. The results show there was no statistically significant association between ADHD medication use and CVDs in general, but the pooled risk ratio does not exclude a modest risk increase, especially for the risk of cardiac arrest and tachyarrhythmias. The risk of CVDs among females and those with pre-existing CVDs, and the long-term risk associated with ADHD medication use require further evaluation.
In study IV, we assessed the association between the long-term use of ADHD medication and the risk of CVDs using a nested case-control design. We found longer duration of ADHD medication use was associated with an increased risk of CVDs compared with non-use. A one-year increase use of ADHD medication was associated with a 7% of increased risk of CVDs. A higher cumulative dose of ADHD medications was also associated with an increased risk of CVDs.
List of papers:
I. Zhang L, Reif A, Du Rietz E, Lagerberg T, Butwicka A, D’Onofrio BM, Johnell K, Pedersen NL, Larsson H, Chang Z. Comedication and polypharmacy with ADHD medications in adults: a Swedish nationwide study. Journal of Attention Disorders. 2021;25(11):1519-28.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Zhang L, Du Rietz E, Kuja‐Halkola R, Dobrosavljevic M, Johnell K, Pedersen NL, Larsson H, Chang Z. Attention‐deficit/hyperactivity disorder and Alzheimer’s disease and any dementia: A multi‐generation cohort study in Sweden. Alzheimer’s & Dementia. 2022;18(6):1155-63.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, Cortese S, D’Onofrio BM, Larsson H, Chang Z. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Network Open. 2022;5(11):e2243597.
Fulltext (DOI)
Pubmed
IV. Zhang L, Li L, Pontus A, D’Onofrio BM, Johnell K, Larsson H, Chang Z. ADHD medications and long-term risk of cardiovascular diseases: a nationwide nested case-control study in Sweden.[Manuscript]
I. Zhang L, Reif A, Du Rietz E, Lagerberg T, Butwicka A, D’Onofrio BM, Johnell K, Pedersen NL, Larsson H, Chang Z. Comedication and polypharmacy with ADHD medications in adults: a Swedish nationwide study. Journal of Attention Disorders. 2021;25(11):1519-28.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Zhang L, Du Rietz E, Kuja‐Halkola R, Dobrosavljevic M, Johnell K, Pedersen NL, Larsson H, Chang Z. Attention‐deficit/hyperactivity disorder and Alzheimer’s disease and any dementia: A multi‐generation cohort study in Sweden. Alzheimer’s & Dementia. 2022;18(6):1155-63.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, Cortese S, D’Onofrio BM, Larsson H, Chang Z. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Network Open. 2022;5(11):e2243597.
Fulltext (DOI)
Pubmed
IV. Zhang L, Li L, Pontus A, D’Onofrio BM, Johnell K, Larsson H, Chang Z. ADHD medications and long-term risk of cardiovascular diseases: a nationwide nested case-control study in Sweden.[Manuscript]
Institution: Karolinska Institutet
Supervisor: Chang, Zheng
Co-supervisor: Larsson, Henrik; Pedersen, Nancy; Johnell, Kristina
Issue date: 2023-01-16
Rights:
Publication year: 2023
ISBN: 978-91-8016-892-2
Statistics
Total Visits
Views | |
---|---|
Developmental ... | 827 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Developmental ... | 31 | 53 | 44 | 47 | 33 | 32 | 40 |
File Visits
Views | |
---|---|
Thesis_Le_Zhang.pdf | 416 |
2.kappa_LZ_20230109_test print 3.pdf | 4 |
Top country views
Views | |
---|---|
Sweden | 301 |
United States | 110 |
United Kingdom | 78 |
Ireland | 70 |
Germany | 25 |
China | 19 |
Australia | 18 |
Canada | 18 |
South Korea | 11 |
Netherlands | 9 |
Top cities views
Views | |
---|---|
Dublin | 62 |
Stockholm | 62 |
Sundbyberg | 22 |
Uppsala | 20 |
Solna | 15 |
Malmo | 12 |
Mariestad | 11 |
Örebro | 9 |
Gothenburg | 7 |
Skövde | 7 |